Market Minds Advisory
Magnetoencephalography Market

Magnetoencephalography Market: Room-Temperature Sensors Free Brain Imaging From the Helium Tank

Optically pumped magnetometers are freeing magnetoencephalography from liquid helium cooling and fixed-head positioning, turning a research-only modality confined to a handful of academic centers into equipment hospitals can deploy for routine epilepsy and pediatric cases.

Lead Analyst

Alice Ballenger

Published

August 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$0.3BMarket Size 2025
2036 FORECAST VALUE$1.3BBase Case , 2026 to 2036
CAGR 2026 TO 203613.5 %Bull 14.9% / Bear 12.1%
INCREMENTAL OPPORTUNITY$0.9BNet 10- year value creation
EXPANSION MULTIPLE3.55x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

Optically pumped magnetometer sensors, which operate at room temperature and mount on a lightweight wearable helmet, are ending magnetoencephalography's decades-long dependence on liquid helium cooling and fixed-position cryogenic dewars, opening the technology to a far broader set of hospitals and patient populations than before.
Demand concentrates in epilepsy presurgical mapping, where precise localization of seizure activity guides resection planning, and in pediatric neurology, where wearable OPM helmets tolerate the head movement conventional SQUID systems cannot accommodate. OPM-based wearable systems, still a small share of the roughly four hundred installed systems worldwide, are growing fastest as the technology moves from single research labs toward multi-site clinical deployment. North America holds the largest installed base on concentrated academic medical center density.
Competitive intensity concentrates among a handful of whole-system manufacturers, since building either a cryogenic SQUID array or a calibrated OPM sensor helmet requires specialized physics and engineering few companies possess. Newer OPM entrants are challenging decades-old SQUID incumbents directly, forcing established manufacturers to develop their own room-temperature sensor programs or risk losing the next generation of clinical and research installations entirely. That competitive pressure keeps intensifying each quarter.
Market Definition
The magnetoencephalography market covers whole-head and portable systems that measure the magnetic fields generated by neuronal electrical activity in the brain, including cryogenic SQUID-based systems, optically pumped magnetometer systems, and hybrid configurations, along with associated magnetically shielded rooms and analysis software sold as part of a system purchase. It excludes electroencephalography systems that do not incorporate magnetic sensing, magnetic resonance imaging equipment, and standalone brain-computer interface devices.
Base Year Value
$0.3B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
13.5% base case. Bull 14.9%. Bear 12.1%.
Fastest Growth Segment
OPM-Based Wearable MEG Systems: 22.0% CAGR
Fastest Growth Country
China: 18.5% CAGR
Fastest Growth Region
South Asia and Pacific: 15.6% CAGR
Largest Region
North America: 31% of 2025 global value
Market Leaders
MEGIN Oy, CTF MEG International Services, Ricoh Company Ltd., QuSpin Inc., Cerca Magnetics Limited. Source: MMA Analysis based on company disclosures.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Magnetoencephalography Market Forecast Scenarios

magnetoencephalography-market-size-forecast-scenario-1787305501531
Between 2020 and 2025 the market grew at roughly 12.0% a year, as the first commercial OPM-based systems reached early-adopter research institutions following years of academic prototype development, while the installed base of conventional cryogenic SQUID systems grew only modestly through mostly replacement purchases at existing centers. That early period established credibility OPM systems needed before hospitals would consider a purchase.
The base case carries the market to a 13.5% CAGR on three mechanisms. First, OPM systems keep reaching commercial maturity, letting more hospitals justify a MEG purchase without the ongoing helium supply cost and dedicated cryogenics staffing a SQUID system requires. Second, pediatric epilepsy centers increasingly adopt wearable systems specifically because children cannot reliably hold still inside a fixed-position scanner. Third, a wider base of neuroscience research funding keeps expanding beyond the small number of institutions that historically dominated MEG research entirely.
The bull case reaches 14.9% if OPM system reliability and channel count improve fast enough to fully match SQUID diagnostic performance within the forecast window. The bear case falls to 12.1% if OPM sensor calibration drift and magnetic shielding requirements prove harder to solve at clinical scale than early research deployments suggested, slowing broader hospital adoption meaningfully.

OPM Sensors Are Rewriting Who Can Afford a MEG System

Three forces converge on this market at once. Helium supply cost and availability keep pressuring the economics of conventional cryogenic systems, OPM sensor technology keeps closing the channel-count and sensitivity gap with SQUID arrays, and clinical epilepsy centers keep demonstrating that precise seizure localization measurably improves surgical outcomes. Manufacturers still relying purely on legacy cryogenic architecture risk losing share to faster-moving OPM entrants. Buyers increasingly w
MARKET CONCENTRATION (CR5)68%Top five manufacturers hold a dominant combined position
AVERAGE SYSTEM PRICE$1.8MWhole-head systems still remain a substantial capital investment
TOP PRODUCING COUNTRY SHARE29%United States leads the global installed system base
INSTALLED BASE WORLDWIDE~400 systemsTotal global count remains small relative to imaging modalities
HELIUM COST SHARE14% of opexCryogenic cooling still burdens conventional system operating budgets
RESEARCH FUNDING SHARE42% of revenueAcademic and government grants still fund a large share
Commercially, the market splits between conventional cryogenic SQUID systems, priced at the higher end but backed by decades of validated clinical performance data, and newer OPM-based systems, priced lower on a per-channel basis but still building the same depth of clinical validation literature. Research institutions purchase across both categories depending on specific study requirements, while hospitals increasingly favor OPM systems for their lower operating cost and pediatric compatibility specifically.
Over the next decade the defining question is whether OPM systems fully displace cryogenic SQUID architecture across both research and clinical settings, or whether SQUID systems retain a durable niche in applications demanding the highest possible channel density and signal sensitivity that current OPM arrays cannot yet match consistently.
"People keep asking when OPM will kill off SQUID entirely, and that framing misses what is actually happening. Hospitals that could never justify a helium-cooled system are buying OPM systems today, which means this market is growing mostly by reaching buyers who were never in it before, not by cannibalizing the old guard."
Director, Neurodiagnostic Imaging Practice · MMA Medical Devices / Neurodiagnost

Market Trends

OPM Helmets Enable Naturalistic, Movement-Tolerant Brain Imaging

Optically pumped magnetometer sensors, mounted in a lightweight three-dimensional printed helmet that conforms to individual head shape, let patients move naturally during scanning rather than remaining perfectly still inside a fixed cryogenic dewar, a requirement conventional SQUID systems cannot relax without significant signal degradation. Cerca Magnetics and QuSpin have both commercialized helmet-based systems since 2022, targeting pediatric epilepsy centers and movement disorder research specifically, where the ability to scan a moving or actively behaving patient opens entirely new clinical and research applications SQUID systems structurally cannot address regardless of engineering refinement.
Market Impact: Guides planning for 50 million pati

Helium Supply Volatility Pushes Buyers Toward Room-Temperature Systems

Global medical helium supply has faced repeated shortages since 2022, driven by concentrated production in a small number of countries and competing demand from semiconductor manufacturing and other cryogenic applications, directly raising the operating cost and supply reliability risk of conventional SQUID-based MEG systems that require continuous liquid helium replenishment. Hospitals evaluating a new MEG purchase increasingly weight this operating risk heavily against OPM systems that eliminate cryogenic cooling entirely, a consideration that barely factored into purchasing decisions before the shortages began affecting research and clinical budgets directly. That risk weighting shift is already visible in procurement discussions.
Market Impact: Cuts ownership cost 30% to 45%

Market Opportunities and Growth Drivers

Epilepsy Surgical Volume Grows as Presurgical Mapping Improves

Drug-resistant epilepsy affects a meaningful share of the roughly fifty million people living with epilepsy worldwide, and surgical resection remains the most effective treatment for eligible candidates, but success depends heavily on precisely localizing the seizure focus before operating. MEG's ability to localize epileptiform activity with millimeter-scale spatial precision, validated across decades of published clinical literature, has made it an increasingly standard component of comprehensive presurgical evaluation at major epilepsy centers, driving recurring capital equipment demand as centers upgrade aging systems and new centers build out comprehensive epilepsy surgery programs entirely.
Market Impact: Adds 10 to 15 minutes setup

OPM Systems Lower the Capital and Operating Barrier to Entry

Conventional cryogenic MEG systems require dedicated liquid helium infrastructure, specialized cryogenics staffing, and a substantial magnetically shielded room, together pushing total cost of ownership well beyond what many mid-sized hospitals could justify historically. OPM-based systems eliminate the helium infrastructure entirely and require meaningfully less shielded room complexity, lowering both upfront capital and ongoing operating cost enough that hospital systems previously priced out of MEG entirely are now evaluating a first purchase, expanding the addressable buyer base well beyond the small number of major academic medical centers that historically dominated the installed base.
Market Impact: Leaves under 20% OPM-based

Market Restraints and Challenges

OPM Sensor Calibration Drift Complicates Clinical Reliability

Optically pumped magnetometers require precise magnetic field zeroing and periodic recalibration to maintain measurement accuracy, and the root cause is that the atomic vapor cells at the heart of each sensor are sensitive to small temperature and magnetic field fluctuations that cryogenic SQUID sensors do not face similarly. This calibration sensitivity adds workflow complexity and occasional measurement inconsistency that clinical users evaluating OPM systems against established SQUID performance still weigh carefully. Manufacturers are mitigating the problem with automated calibration routines and improved magnetic shielding materials that reduce drift-related measurement issues.
Market Impact: Cuts scan failures 35% to 45%

Small Installed Base Limits Clinical Validation Literature

With roughly four hundred systems installed worldwide and OPM systems representing a small fraction of that total, published clinical validation literature for OPM-based diagnostic performance remains thinner than the decades of accumulated SQUID literature clinicians rely on, and the root cause is that the technology has not yet accumulated comparable years of clinical deployment. This thin evidence base slows purchasing decisions at conservative academic medical centers and complicates reimbursement conversations with payers unfamiliar with the newer technology. Manufacturers are mitigating the gap by funding multi-site validation studies and publishing comparative performance data against established SQUID benchmarks.
Market Impact: Helium costs rose 25% to 40%
3 additional market trends, 4 additional growth drivers, and 3 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

Segmentation follows sensor technology, a single engineering-based logic distinguishing how each system measures neuromagnetic activity. Software analytics and shielded-room infrastructure are treated as separate commercial dimensions, not parallel segments within this sensor-based framework. Each technology carries its own cost structure, achievable channel count, and clinical validation depth, so commercial position tracks sensor physics rather than end application.
magnetoencephalography-market-market-share-analysis-1787305502206

OPM-Based Wearable MEG Systems

OPM-based wearable systems grow fastest at 22.0%, about 1.63 times the overall rate, as room-temperature sensor helmets reach commercial maturity and open MEG purchasing to hospitals that could never justify conventional cryogenic infrastructure. Cerca Magnetics and QuSpin lead commercial deployment, targeting pediatric epilepsy centers and movement-tolerant research applications where wearable, naturalistic scanning delivers genuine clinical advantage over fixed-position alternatives. Channel counts, while improving steadily, still trail the highest-end conventional SQUID arrays for applications demanding maximum spatial resolution across the full scalp simultaneously. Adoption is fastest among hospitals purchasing a first MEG system rather than replacing an existing cryogenic installation, reflecting genuinely new market creation rather than pure technology substitution within the existing installed base.
CAGR 22.0%

Hybrid SQUID-OPM Systems

Hybrid systems combining conventional SQUID sensor arrays with supplementary OPM sensors grow at 16.5%, the second-fastest category, letting research institutions capture SQUID's established high-channel-count performance while adding OPM's movement tolerance for specific study protocols requiring both capabilities within one facility. This hybrid approach appeals particularly to established academic research centers with existing SQUID infrastructure looking to extend capability without a full system replacement, representing an incremental upgrade path rather than a wholesale technology transition. Commercial availability remains limited to a small number of specialized manufacturers capable of integrating both sensor architectures within a single coherent measurement platform reliably. Growth here reflects cautious incumbent adoption rather than the more disruptive market expansion driving pure OPM system growth.
CAGR 16.5%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

North America holds the largest installed base on concentrated academic medical center density, Western Europe follows closely on deep neuroscience research infrastructure, and South Asia and Pacific compounds fastest off a small existing base. East Asia and smaller regions continue building capacity from comparatively modest current installed positions.

North America

United States academic medical centers hold the largest single concentration of installed MEG systems worldwide, with major epilepsy surgery programs at institutions across the country anchoring recurring replacement and upgrade demand alongside steady neuroscience research funding through the National Institutes of Health. QuSpin, based in Colorado, and several leading OPM research groups have made the country a genuine hub for room-temperature sensor development specifically, not merely a purchasing market for technology developed elsewhere. Canada's CTF MEG International Services adds domestic manufacturing depth alongside the American research base. Growth trails East Asia and South Asia and Pacific because the region's installed base is already the world's largest, leaving incremental replacement and OPM conversion as the primary demand driver.
Share: 31% | CAGR: 13.0% (2026 to 2036)

Western Europe

The United Kingdom has emerged as the global hub for OPM-MEG innovation, with the University of Nottingham's pioneering research directly spinning out Cerca Magnetics as a commercial manufacturer now selling systems internationally. Finland's MEGIN, tracing its lineage to some of the earliest commercial MEG systems ever built, anchors the region's conventional SQUID manufacturing base and maintains deep installed relationships across European research hospitals. Germany and France both host substantial neuroscience research infrastructure driving steady replacement and expansion demand at established academic centers. Growth trails East Asia and South Asia and Pacific as the region's research infrastructure and installed base are both already comparatively mature relative to faster-growing emerging markets. That combination keeps the region a genuine innovation center.
Share: 26% | CAGR: 12.0% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
magnetoencephalography-market-country-cagr-analysis-1787305502727

Where MEG Manufacturers Can Defend and Grow Share

Four commercial moves separate manufacturers capturing the OPM-driven market expansion from those losing ground to it: clinical validation investment, hospital financing partnerships, hybrid upgrade pathways, and shielded-room bundling services. Each move converts a technical or clinical evidence advantage into a defensible commercial position competitors without matching validation depth or financing reach cannot easily replicate quickly.

Fund Multi-Site Clinical Validation Studies for OPM Performance

The thin published literature comparing OPM diagnostic performance against decades of established SQUID benchmarks remains the single biggest barrier to conservative academic medical center adoption, and manufacturers funding rigorous multi-site validation studies directly address that gap rather than waiting for independent researchers to generate the evidence organically over many additional years. Cerca Magnetics and QuSpin have both invested in sponsored validation research, and early data suggests this investment shortens purchasing committee decision timelines by roughly 20% to 30% at institutions that had been waiting for stronger published evidence before committing capital.
Market Impact: Cuts purchasing decision timelines

Offer Equipment Financing to Reach Mid-Sized Hospital Buyers

OPM systems have lowered the price barrier to MEG ownership meaningfully, but a system still represents a substantial capital commitment for hospitals without the research grant funding academic medical centers typically draw on for equipment purchases. Manufacturers offering structured financing and leasing arrangements open the buyer pool to mid-sized hospital systems that would otherwise need to compete for scarce capital budget against many other priorities, and financing availability increasingly influences which manufacturer wins a given hospital's business as much as raw system specification does at this point. Financed deals now close roughly 2 times faster.
Market Impact: Expands the addressable buyer pool

Sell Hybrid Upgrade Paths to Existing SQUID Installations

Academic centers with existing cryogenic SQUID installations represent a captive upgrade opportunity rather than a cold sales prospect, and manufacturers offering hybrid OPM add-on modules that integrate with an existing SQUID system capture incremental revenue without requiring the institution to justify an entirely new capital purchase from scratch. This upgrade path also builds a natural migration bridge toward eventual full OPM adoption as the technology matures further, keeping the manufacturer relationship intact across what would otherwise be a multi-decade replacement cycle gap between major purchases. Upgrade modules typically run 15% to 25% of a full system's list price.
Market Impact: Adds $150,000 to $400,000 in increm

Bundle Shielded-Room Infrastructure Into the System Sale

Magnetically shielded rooms remain a required, often underestimated cost component of any MEG installation, and manufacturers who bundle shielded-room design, installation, and commissioning directly into the system sale rather than leaving hospitals to source that infrastructure separately capture additional project revenue while reducing installation delays that damage the overall purchasing experience. This bundling approach is particularly valuable for OPM systems, where reduced shielding requirements relative to SQUID systems can meaningfully lower total project cost when properly engineered and communicated to the buyer upfront. Bundled shielding packages typically add 15% to 25% to total contract value while shortening installation timelines.
Market Impact: Adds 15% to 25% to total contract v

Who Controls the Margin Pool

Concentration sits at a high CR5 of 68%, with a gap separating a handful of established whole-system manufacturers from newer OPM-focused entrants still scaling commercial operations. MEGIN and CTF MEG anchor the conventional SQUID incumbent position, while QuSpin and Cerca Magnetics lead OPM commercialization. Few other companies possess the physics and engineering depth required to build a complete whole-head system.
Current competitive activity runs along three lines: OPM sensor performance improvement, where QuSpin and Cerca Magnetics race to close the channel-count gap with SQUID arrays; clinical validation evidence generation; and hybrid system development, where incumbents attempt to bridge legacy installations toward newer sensor technology. All participants are assessed on one consistent basis, annual revenue from MEG systems.

Pressure is building from two directions. OPM-focused entrants are winning first-time hospital purchases that would never have considered a conventional cryogenic system, expanding the addressable market in ways incumbents cannot easily contest. Meanwhile established SQUID manufacturers are racing to develop credible OPM offerings of their own rather than cede the fastest-growing segment to newer competitors. Rankings over the next five years will likely shift toward companies combining strong OPM technology with the clinical validation depth incumbents already possess.
magnetoencephalography-market-company-positioning-matrix-1787305503250

Competitive Moat and Risk Dimensions

MEGIN OY

Moat: Largest installed clinical SQUID base

MEGIN, tracing its technology lineage to some of the earliest commercial MEG systems built, holds the largest installed base of clinical SQUID systems worldwide, giving it decades of accumulated clinical validation literature and deep relationships with major epilepsy surgery centers that newer entrants cannot replicate without years of comparable clinical deployment history.
MEGIN OY

Risk: Cryogenic helium supply cost exposure

MEGIN's core installed base depends on continuous liquid helium supply, exposing both the company and its hospital customers to ongoing helium price volatility and availability risk that OPM competitors have eliminated entirely from their value proposition. Should helium supply constraints worsen further, MEGIN's conventional SQUID franchise could face accelerating pressure from hospitals reconsidering total cost of ownership.
QUSPIN INC.

Moat: Pioneering commercial OPM sensor IP

QuSpin's early and sustained investment in optically pumped magnetometer sensor development has given it some of the industry's most mature commercial OPM sensor technology, positioning it as a preferred component supplier to other system integrators as well as a direct competitor in finished helmet systems, a dual-position advantage few competitors currently match.
QUSPIN INC.

Risk: Small company limited manufacturing scale

As a smaller, more narrowly focused company than diversified medical device incumbents, QuSpin faces real constraints on manufacturing scale and balance sheet depth relative to larger competitors that could accelerate their own OPM programs with substantially greater capital resources once they commit fully to the technology transition underway.

Players Tracked

Prominent Players

MEGIN Oy
CTF MEG International Services
Ricoh Company Ltd.
QuSpin Inc.
Cerca Magnetics Limited

Other Key Players

Twinleaf LLC
FieldLine Inc.
Compumedics Limited
Tristan Technologies
Hitachi Ltd.
Magnetic Shields Limited
ETS-Lindgren
Vacuumschmelze GmbH
Cryomech Inc.
Janis Research Company
Supracon AG
Quantum Design International
Sumitomo Heavy Industries
Bruker Corporation
Elekta AB

Recent Developments

MARCH 2025

Cerca Magnetics closes new funding round to scale OPM-MEG manufacturing

Cerca Magnetics completed a new equity funding round to expand manufacturing capacity for its OPM-based wearable MEG helmet systems and support broader international commercial deployment. This was an equity financing round, not an acquisition or merger, funded by existing and new institutional investors backing the company's continued commercial expansion.
Signal: Continued investor appetite for OPM-focuse
SEPTEMBER 2024

MEGIN signs global distribution agreement with medical imaging distributor

MEGIN signed a new distribution agreement expanding its international sales and service coverage through an established medical imaging equipment distributor's existing hospital relationships. This was a commercial distribution agreement, not a joint venture or acquisition, extending MEGIN's market reach without altering its ownership or manufacturing structure.
Signal: Extending distribution reach rather than p
JANUARY 2025

FieldLine and children's hospital network launch pediatric epilepsy imaging pilot

FieldLine Inc. partnered with a multi-site children's hospital network to launch a clinical pilot program evaluating its OPM-based system for pediatric epilepsy presurgical mapping across several participating locations. This was a clinical research partnership, not an acquisition or joint venture, generating real-world pediatric performance data for both parties.
Signal: A multi-site pediatric pilot signals growi

Sensor Components and Shielding Materials Drive Cost

Precision sensor components, including SQUID electronics for conventional systems and laser and vapor cell assemblies for OPM sensors, together with magnetic shielding materials such as mu-metal, account for a substantial share of production COGS, sourced from a concentrated group of specialty component manufacturers with few alternative suppliers. Cryogenic infrastructure components for SQUID systems add a further significant cost layer that OPM systems largely avoid.
The clearest recent volatility event traces to the global medical and industrial helium shortages beginning in 2022, which the United States Geological Survey documented as driven by concentrated production capacity and unplanned outages at major helium extraction facilities. Several SQUID system operators reported sharply higher helium procurement costs and supply interruptions that complicated continuous cryogenic operation, raising conventional system operating budgets across the industry during the worst periods.

Exposure varies sharply by system technology. Conventional SQUID system operators remain directly exposed to helium price and supply volatility with no practical substitute available, while OPM system operators face none of that exposure, instead facing exposure concentrated in optical and vapor cell component sourcing. This divergence increasingly factors into total cost of ownership comparisons that influence purchasing decisions across cost-conscious hospital buyers evaluating both technologies.
magnetoencephalography-market-cost-volatility-analysis-1787305503444

Secure Long-Term Helium Supply Contracts for SQUID Systems

SQUID system manufacturers and large hospital operators are increasingly negotiating direct long-term helium supply agreements with producers, securing priority allocation and more predictable pricing ahead of future shortage events rather than relying on spot market purchasing during periods of industry-wide constraint. This mirrors long-term sourcing practices already standard across other cryogenics-dependent scientific instrumentation fields facing similar supply constraints.

Adopt Helium Recycling and Recondensing Systems

Several manufacturers now offer helium recondensing systems that capture and recycle boil-off gas rather than venting it, meaningfully reducing ongoing helium consumption and associated cost exposure for hospitals continuing to operate conventional cryogenic SQUID installations over their full service life. Hospitals adopting recondensing systems typically recover the added equipment cost within three to four years of continuous helium savings.

Diversify OPM Component Sourcing Across Multiple Suppliers

OPM system manufacturers are qualifying multiple sources for critical laser and vapor cell components rather than depending on single suppliers, reducing exposure to any one facility disruption as the OPM component supply base continues maturing alongside broader technology adoption industry-wide. This diversification mirrors sourcing discipline already standard across other precision optical and photonics component supply chains broadly.

Portfolio Architecture for Margin Defence

The portfolio splits into three tiers with substantial margin separation. Conventional SQUID systems compete on established clinical performance and validated reliability, earning solid margins defended through decades of accumulated engineering refinement and service relationships. Certified premium OPM systems earn strong margins as well, commanding pricing that reflects genuine clinical differentiation for movement-tolerant and pediatric applications SQUID systems cannot match. That gap widen
The tension between defending legacy SQUID revenue and investing aggressively in OPM development shapes manufacturer strategy directly: incumbents that protect SQUID margins too conservatively risk ceding the fastest-growing segment entirely to newer competitors, while companies that abandon SQUID support too quickly risk alienating the large installed base still generating substantial service and upgrade revenue today.

High-value pools concentrate in OPM systems serving pediatric and movement-tolerant applications and in hybrid upgrade offerings for existing installations, where technical differentiation justifies premium pricing few competitors can match. The emerging next-generation fully mobile and multi-site deployment tier currently earns unevenly as manufacturers absorb development cost against still-maturing clinical adoption. That unevenness should ease as mobile deployment platforms accumulate more mature commercial and clinical validation.

Volume / Commodity-Adjacent Tier

Conventional cryogenic SQUID systems sold on established clinical performance and decades of validated reliability to research and clinical buyers., where accumulated engineering refinement and service depth determine which manufacturers can sustain acceptable margin against newer competitors.
Gross Margin: 32-45%

Premium / Certified Tier

OPM-based wearable systems commanding premium pricing for pediatric and movement-tolerant applications with genuine clinical differentiation., where buyers pay durable premiums for capability conventional cryogenic systems simply cannot deliver regardless of engineering refinement.
Gross Margin: 48-62%

Sustainability / Regulatory / Next-Generation Tier

Fully mobile and multi-site deployable systems still absorbing development investment against still-maturing clinical adoption and validation., where manufacturers are betting development capital on formats they expect hospitals to demand as standard within several years.
Gross Margin: 25-55%
magnetoencephalography-market-portfolio-architecture-1787305503941

How MEG System Demand Actually Recurs

Demand here runs on an unusually long capital cycle even by medical imaging standards. A research institution or hospital buys a system and operates it for fifteen years or longer before replacement, meaning a single sale represents a decades-long relationship spanning service contracts, software upgrades, and eventual replacement rather than any form of recurring per-unit purchase.
Adoption depth varies sharply by buyer type. Academic research institutions integrate MEG systems deeply into multi-year grant-funded research programs, making the relationship durable but the purchasing cycle slow and heavily dependent on external funding availability outside the manufacturer's control. Hospital epilepsy centers, by contrast, evaluate purchases more directly against clinical volume and reimbursement economics, creating a purchasing decision manufacturers can influence more directly through evidence and financing.

Buyer profiles are shifting generationally as hospital neurology departments, not only academic research centers, increasingly drive purchasing decisions as OPM systems lower the barrier to clinical rather than purely research deployment. Younger neurologists trained during residency on the clinical value of precise seizure localization increasingly expect MEG access as standard epilepsy center infrastructure rather than a specialized research-only capability. That generational shift is accelerating steadily across most major markets.
magnetoencephalography-market-end-use-penetration-index-1787305504429

Where MEG Value Concentrates Next

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / OPM CLINICAL VALIDATION INVESTMENT

Fund validation studies before conservative buyers demand them

The thin published literature comparing OPM performance against decades of SQUID benchmarks remains the single largest barrier standing between OPM manufacturers and broader academic medical center adoption. Companies investing in rigorous multi-site validation now, rather than waiting for independent researchers to generate that evidence organically, will shorten their own purchasing decision timelines meaningfully relative to competitors still building their evidence base. This investment compounds as each published study makes the next hospital's purchasing committee decision easier to secure., building a credibility advantage rivals will find hard to match.
02 / HOSPITAL FINANCING PARTNERSHIPS

Build financing pathways to reach mid-sized hospital buyers

OPM systems have genuinely lowered MEG's price barrier, but the addressable buyer pool only expands fully if manufacturers also solve the capital budgeting challenge mid-sized hospitals face without academic research grant funding to draw on. Structured financing and leasing arrangements are becoming a genuine competitive differentiator, one buyers now factor into vendor selection nearly as heavily as clinical specification itself. Manufacturers without financing options available will increasingly lose deals to competitors who can make the purchase decision easier on a hospital's capital budget cycle.
03 / INCUMBENT SQUID TRANSITION STRATEGY

Develop credible OPM offerings before losing the installed base

Established SQUID manufacturers face a genuine strategic choice between developing credible OPM technology internally or risking gradual displacement as newer, more focused competitors capture the fastest-growing segment of the market entirely. Hybrid upgrade paths offer a bridge strategy that protects existing installed-base relationships while building toward eventual full OPM capability. Incumbents moving decisively now will retain far more of their installed base than those treating OPM as a peripheral experiment rather than a core strategic priority., a distinction that will define which manufacturers still matter a decade from now.
04 / HELIUM SUPPLY RISK MANAGEMENT

Treat helium exposure as a durable competitive disadvantage for SQUID

Helium supply volatility since 2022 has already meaningfully shifted total cost of ownership calculations in OPM's favor, and that dynamic shows no clear sign of reversing given concentrated global helium production and rising competing industrial demand. SQUID manufacturers and hospital operators without helium recycling infrastructure or long-term supply contracts in place face a durable cost disadvantage that will only compound over each system's fifteen-year or longer operating life. Manufacturers who help hospitals plan around that exposure now will earn a trust advantage that outlasts any single product cycle.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Magnetoencephalography Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Magnetoencephalography Exposure Evaluation 2025-26
CLIENT PROFILE
A regional children's hospital network operating three pediatric epilepsy centers approached MMA while evaluating its first MEG system purchase to support an expanding presurgical epilepsy evaluation program. The client reported an approved capital budget of roughly USD 2.4 million for the initiative, with no prior in-house MEG experience across its clinical or research staff (client-reported, unverified by MMA).
STRATEGIC CHALLENGE
Clinical leadership favored OPM technology specifically for its pediatric movement tolerance, but the capital committee lacked confidence comparing OPM systems against conventional SQUID alternatives given the thinner published clinical validation literature and limited internal expertise evaluating unfamiliar sensor technology against decades-established clinical standards. The board wanted a defensible decision within the fiscal year, not another cycle of unresolved internal debate.
MMA APPROACH
MMA benchmarked clinical validation evidence and total cost of ownership across three OPM and two SQUID system manufacturers against the client's specific pediatric epilepsy caseload profile, modeled financing options against the approved capital budget, and assessed each manufacturer's shielded-room infrastructure requirements and installation timeline for the client's existing facility constraints.
KEY FINDINGS
  1. OPM systems reduced projected scan failure rates for the client's pediatric patient population by an estimated forty percent relative to conventional SQUID alternatives, directly addressing the clinical team's primary stated concern.
  2. Total cost of ownership over a projected ten-year period favored the OPM option by a meaningful margin once eliminated helium infrastructure and reduced shielded-room complexity were fully accounted for in the comparison.
  3. Two of three benchmarked OPM manufacturers could provide multi-site published validation data specific to pediatric epilepsy applications, addressing the capital committee's evidence concern directly and substantively.
  4. Manufacturer financing options varied enough to shift the effective near-term capital outlay meaningfully within the client's approved budget range, making financing terms a genuinely material selection factor (client-reported, unverified by MMA).
CLIENT PROFILE
A regional children's hospital network operating three pediatric epilepsy centers approached MMA while evaluating its first MEG system purchase to support an expanding presurgical epilepsy evaluation program. The client reported an approved capital budget of roughly USD 2.4 million for the initiative, with no prior in-house MEG experience across its clinical or research staff (client-reported, unverified by MMA).
STRATEGIC CHALLENGE
Clinical leadership favored OPM technology specifically for its pediatric movement tolerance, but the capital committee lacked confidence comparing OPM systems against conventional SQUID alternatives given the thinner published clinical validation literature and limited internal expertise evaluating unfamiliar sensor technology against decades-established clinical standards. The board wanted a defensible decision within the fiscal year, not another cycle of unresolved internal debate.
MMA APPROACH
MMA benchmarked clinical validation evidence and total cost of ownership across three OPM and two SQUID system manufacturers against the client's specific pediatric epilepsy caseload profile, modeled financing options against the approved capital budget, and assessed each manufacturer's shielded-room infrastructure requirements and installation timeline for the client's existing facility constraints.
KEY FINDINGS
  1. OPM systems reduced projected scan failure rates for the client's pediatric patient population by an estimated forty percent relative to conventional SQUID alternatives, directly addressing the clinical team's primary stated concern.
  2. Total cost of ownership over a projected ten-year period favored the OPM option by a meaningful margin once eliminated helium infrastructure and reduced shielded-room complexity were fully accounted for in the comparison.
  3. Two of three benchmarked OPM manufacturers could provide multi-site published validation data specific to pediatric epilepsy applications, addressing the capital committee's evidence concern directly and substantively.
  4. Manufacturer financing options varied enough to shift the effective near-term capital outlay meaningfully within the client's approved budget range, making financing terms a genuinely material selection factor (client-reported, unverified by MMA).
RECOMMENDED STRATEGY
Phase 1: Phase 1 (0 to 4 months): Select the OPM manufacturer with the strongest pediatric epilepsy validation data and most favorable financing terms. Phase 2: Phase 2 (4 to 10 months): Complete facility preparation and shielded-room installation while training clinical and technical staff on the new system. Phase 3: Phase 3 (10 to 24 months): Deploy across all three network locations on a staggered schedule, capturing early performance data to support the network's own future publication efforts.
OUTCOME
The client selected an OPM system manufacturer and began Phase 1 deployment on schedule, reporting a projected reduction in pediatric anesthesia use during scanning of roughly 30% based on early clinical experience at the first deployed location. The network's financing structure kept the initiative within its original approved capital budget (client-reported, unverified by MMA).

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Magnetoencephalography Market?

The magnetoencephalography market was valued at USD 0.32 billion in 2025. Growth is driven by OPM sensor commercialization, expanding epilepsy surgical volume, and lower total cost of ownership for hospital buyers.

How large will the Magnetoencephalography Market be by 2036?

The market is projected to reach USD 1.29 billion by 2036 under the base case scenario. That reflects an expansion multiple of roughly 3.55 times the 2026 value.

What is the CAGR for the Magnetoencephalography Market 2026 to 2036?

The base case CAGR is 13.5%, with a bull case of 14.9% and a bear case of 12.1%. OPM clinical validation progress is the main swing factor between scenarios.

Which segment is growing fastest?

OPM-based wearable MEG systems grow fastest at 22.0% CAGR, roughly 1.63 times the overall market rate. Hybrid SQUID-OPM systems follow as the second-fastest segment at 16.5%.

Who are the major companies in the Magnetoencephalography Market?

Leading manufacturers include MEGIN Oy, CTF MEG International Services, Ricoh Company Ltd., QuSpin Inc., and Cerca Magnetics Limited. The top five hold a combined 68% of the market.

Which country is growing fastest?

China is the fastest-growing country at 18.5% CAGR, driven by expanding national brain research initiatives and new institutional purchasing. Domestic hospital and research investment anchors much of that growth.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Sensor Technology

  • SQUID-Based Whole-Head Systems
  • OPM-Based Wearable Systems
  • Hybrid SQUID-OPM Systems
  • Single and Limited-Channel OPM Research Systems
  • MEG-EEG Integrated Diagnostic Systems
  • Refurbished and Legacy SQUID Systems

By End-Use Setting

  • Academic Research Institutions
  • Hospital Epilepsy Surgery Centers
  • Pediatric Neurology Departments
  • Government and Defense Research Laboratories
  • Pharmaceutical Clinical Trial Centers

By Commercial Dimension

  • Direct System Sales
  • Equipment Financing and Leasing
  • Shielded-Room Bundled Contracts
  • Service and Upgrade Agreements

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
The magnetoencephalography market comprises whole-head and portable systems that measure the magnetic fields generated by neuronal electrical activity in the brain, including cryogenic SQUID-based systems, optically pumped magnetometer systems, and hybrid configurations, along with associated magnetically shielded rooms and analysis software sold as part of a system purchase. Electroencephalography systems without magnetic sensing, magnetic resonance imaging equipment, and standalone brain-computer interface devices are excluded.
Quantitative Units
USD millions (current prices); installed system count where applicable
Segmentation Dimensions
By Sensor Technology; By End-Use Setting; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, China, Germany, France, UK, Japan, South Korea, India, Australia, Canada, Brazil, Mexico, Indonesia, Vietnam, Thailand, Malaysia, UAE, Saudi Arabia, South Africa, Nigeria, Turkey, Poland, Netherlands, Italy, Spain, Sweden, Switzerland, Argentina, Colombia, Singapore, and additional markets relevant to this sector
Key Companies Profiled
MEGIN Oy, CTF MEG International Services, Ricoh Company Ltd., QuSpin Inc., Cerca Magnetics Limited, Twinleaf LLC, FieldLine Inc., Compumedics Limited, Tristan Technologies, Hitachi Ltd., Magnetic Shields Limited, ETS-Lindgren, Vacuumschmelze GmbH, Cryomech Inc., Janis Research Company, Supracon AG, Quantum Design International, Sumitomo Heavy Industries, Bruker Corporation, Elekta AB
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-MED-501
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Magnetoencephalography Market Report (2026 to 2036).

The full MMA Magnetoencephalography Market report sizes demand across six sensor technologies, five end-use settings, four commercial dimensions, and seven regions through 2036. It profiles twenty companies on a consistent revenue basis, scoring each on sensor technology maturity, clinical validation depth, and manufacturing scale. Scenario models quantify how OPM validation progress and helium supply volatility move both demand and realizable pricing. The report includes delivered-cost modeling by sensor technology and a manufacturer validation-readiness screen built for hospital procurement and research strategy teams. Regional installed-base tracking rounds out the coverage for capital planning teams.
Sensor technology benchmarking across SQUID and OPM platforms
Clinical validation literature tracking by manufacturer
Helium supply exposure modeling by system technology
Hospital financing and total cost of ownership comparisons
Installed base and replacement-cycle timing by region
OPM adoption scenarios under bull and bear cases

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts